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Abstract
Background: Genetic variability in the regulation of the nitric oxide (NO) pathway may influence hemodynamic changes in
pediatric sepsis. We sought to determine whether functional polymorphisms in DDAH2, which metabolizes the NO synthase
inhibitor asymmetric dimethylarginine (ADMA), are associated with susceptibility to sepsis, plasma ADMA, distinct
hemodynamic states, and vasopressor requirements in pediatric septic shock.
Methodology/Principal Findings: In a prospective study, blood and buccal swabs were obtained from 82 patients #18
years (29 with severe sepsis/septic shock plus 27 febrile and 26 healthy controls). Plasma ADMA was measured using
tandem mass spectrometry. DDAH2 gene was partially sequenced to determine the 2871 6g/7g insertion/deletion and
2449G/C single nucleotide polymorphisms. Shock type (‘‘warm’’ versus ‘‘cold’’) was characterized by clinical assessment.
The 2871 7g allele was more common in septic (17%) then febrile (4%) and healthy (8%) patients, though this was not
significant after controlling for sex and race (p=0.96). ADMA did not differ between 2871 6g/7g genotypes. While
genotype frequencies also did not vary between groups for the 2449G/C SNP (p=0.75), septic patients with at least one
2449G allele had lower ADMA (median, IQR 0.36, 0.30–0.41 mmol/L) than patients with the 2449CC genotype (0.55, 0.49–
0.64 mmol/L, p=0.008) and exhibited a higher incidence of ‘‘cold’’ shock (45% versus 0%, p=0.01). However, after
controlling for race, the association with shock type became non-significant (p=0.32). Neither polymorphism was
associated with inotrope score or vasoactive infusion duration.
Conclusions/Significance: The 2449G polymorphism in the DDAH2 gene was associated with both low plasma ADMA and an
increased likelihood of presenting with ‘‘cold’’ shock in pediatric sepsis, but not with vasopressor requirement. Race, however,
was an important confounder. These resultssupport and justify the need for larger studies in racially homogenous populations to
further examine whether genotypic differences in NO metabolism contribute to phenotypic variability in sepsis pathophysiology.
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Introduction
Cardiovascular dysfunction is common in sepsis and is the
hallmark of septic shock. Classically, patients with septic shock
exhibit hyperdynamic cardiac function and low systemic vascular
resistance (SVR) resulting in hypotension and decreased organ
perfusion [1]. While this ‘‘warm’’ shock state is typical of adults
with sepsis, hemodynamic profiles observed in septic children are
more variable, with an increased incidence of low cardiac output
and elevated SVR, or ‘‘cold’’ shock [2]. Hemodynamic variability
influences therapy, such as choice of vasoactive infusion, and
outcomes, with low SVR associated with increased mortality in
adult septic shock [3] and decreased cardiac output portending
worse survival in pediatric sepsis [4].
The nitric oxide (NO) pathway, through its effects on both
myocardial and vascular function, influences hemodynamic
changes in septic shock. NO acts through cyclic guanosine
monophosphate to sequester intracellular calcium, which enhanc-
es vascular and myocardial muscle relaxation [5]. In sepsis,
evidence supports an overall increase in systemic NO production
[6,7,8]. However, multiple factors can affect tissue-specific NO
signaling, including availability of arginine (the NO synthase
[NOS] substrate) [9], location of distinct NOS isoforms [5], and
presence of endogenous NOS inhibitors, the most important of
which is asymmetric dimethylarginine (ADMA) [10]. Whether
genetic variability in the regulation of NOS activity contributes to
different hemodynamic states observed in pediatric septic shock is
not known.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33355The importance of ADMA in regulating NO has been
increasingly recognized in disorders of endothelial and vascular
dysfunction [10]. ADMA is synthesized by the methylation of
arginine residues on proteins and released into circulation during
catabolism [10]. ADMA inhibits NO production through
competitive binding with arginine for all NOS isoforms and for
cellular uptake [10]. Elevated plasma concentrations of ADMA
are seen in adults with sepsis [11], multi-organ dysfunction [12],
and severe malaria [13] and have shown promise as a biomarker
in cardiovascular [14,15] and renal disease [16]. In pediatric
sepsis, however, ADMA levels are more variable, with an overall
decrease compared with non-septic controls [17].
Genetic polymorphisms in the enzyme dimethylarginine
dimethylaminohydrolase (DDAH), which is responsible for
ADMA metabolism (Figure 1), have been associated with different
levels of ADMA in adult sepsis [11], diabetes mellitus [18], and
pre-eclampsia [19], and co-localization of DDAH with NOS
expression supports a key role for this enzyme in the regulation of
NO activity [10]. Two distinct isoforms exist, with DDAH1
predominating in the liver and kidneys and DDAH2 primarily
found in endothelial, vascular, and immune cells [20]. The
predilection for DDAH2 in vascular tissue suggests that variability
in expression or activity of this enzyme may contribute to
hemodynamic changes observed in sepsis. Polymorphisms in the
DDAH2 gene (OMIM #604744) have been associated with
plasma ADMA levels in adult sepsis [11] and vasopressor use
following cardiac surgery [21]. We therefore hypothesized that two
functional polymorphisms in the promoter region of the DDAH2
gene—the 2871 6g/7g insertion/deletion and 2449G/C single
nucleotide polymorphisms—affect plasma ADMA concentration
and hemodynamic changes in pediatric septic shock.
The objectives of this study were to determine if functional
polymorphisms in the DDAH2 gene were associated with plasma
ADMA concentration, distinct hemodynamic states, and cardio-
vascular dysfunction in pediatric septic shock. We found that the
2449G single nucleotide polymorphism (SNP) within the DDAH2
gene was associated with both decreased plasma ADMA and an
increased likelihood of presenting with ‘‘cold’’ shock in pediatric
sepsis.
Methods
Ethics
Ethics approval was obtained from the Institutional Review
Board of Children’s Memorial Hospital, Chicago, Illinois. Written
informed consent and assent were obtained for study enrollment
and laboratory analysis from parents/guardians and patients (age
$12 years), respectively, with specific consent sought for
genotyping.
Objectives
The objectives of this study were to determine if functional
polymorphisms within the DDAH2 gene influenced susceptibility
to developing severe sepsis or septic shock and were associated
with differences in concentrations of plasma ADMA concentra-
tion, type of shock (‘‘warm’’ versus ‘‘cold’’), and vasopressor
requirement in pediatric patients. We hypothesized that a higher
frequency of rare DDAH2 genotypes would be evident in children
with severe sepsis or septic shock compared with non-septic
controls, the likelihood for septic children to present with ‘‘warm’’
versus ‘‘cold’’ shock would differ by DDAH2 genotype, and genetic
variability would be associated with plasma ADMA on PICU
admission and longitudinal requirement for pharmacologic
hemodynamic support.
Participants
Patients who were #18 years-old and met criteria for severe
sepsis or septic shock as defined by the International Pediatric
Consensus Conference [22] were recruited from a 42-bed
pediatric intensive care unit (PICU) at an academic medical
center between May 2009 and June 2010 (septic patients).
Exclusion criteria were cardiac arrest preceding admission,
treatment with inhaled NO or sildenafil, supplementation with
arginine, citrulline, or carnitine, a metabolic, urea cycle, or
mitochondrial disorder, chronic renal or hepatic impairment,
unrepaired cyanotic heart disease or single-ventricle anatomy,
major surgery within the previous 72 hours, transfer from another
facility with ongoing sepsis .24 hours, and prior study enrollment.
Age-matched control patients from the same hospital were
Figure 1. NO-ADMA-DDAH pathway. Onset of infection in sepsis leads to an up-regulation of inducible nitric oxide synthase (NOS) in response to
lipopolysaccharide and pro-inflammatory cytokines. This consequently increases nitric oxide (NO) production, which has a multitude of effects on
endothelial, vascular, and immune function. Asymmetric dimethylarginine (ADMA) is produced by the methylation of arginine residues on proteins
by the enzyme protein-arginine methyltransferase (PRMT) and metabolized by dimethylarginine dimethylaminohydrolase (DDAH). ADMA
competitively inhibits NOS, thereby limiting NO production.
doi:10.1371/journal.pone.0033355.g001
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evaluated for infection without severe sepsis or shock (febrile
controls) and 2) afebrile patients without evidence of an active
infectious or inflammatory condition undergoing a minor
procedure, such as a hernia repair or endoscopy (healthy controls).
Only those disorders also listed for septic patients (e.g. chronic
renal impairment) were used to exclude controls.
Data Collection
Septic patients were enrolled within 24 hours of PICU
admission or, if already in the PICU, within 24 hours of onset
of severe sepsis or septic shock as defined by initial fever and first
evidence of organ dysfunction. Clinical data were abstracted from
the medical record onto a standardized case report form.
Information was collected on age, sex, race/ethnicity, and severity
of illness indices including Pediatric Index of Mortality (PIM)-2
[23] and Pediatric Logistic Organ Dysfunction (PELOD) scores
[24]. For septic patients, intensity of vasoactive infusion therapy
was determined by calculating the daily maximum inotrope score
(IS) [25] for the first three study days and duration was measured
by the number of vasoactive infusion-free days out of 28. Type of
shock (‘‘warm’’ versus ‘‘cold’’) was categorized based on the initial
clinical assessment of septic patients as documented in the medical
record (Table 1) [26].
Measurement of Plasma ADMA
Blood was collected at the time of study enrollment (day 1) for
septic patients and controls and on day 3 for septic patients. All
specimens were processed in the main hospital laboratory with
immediate centrifugation and storage of plasma at 270uC for
batched analysis. Plasma ADMA was measured by the gold-
standard method of high performance liquid chromatography-
tandem mass spectrometry (LC-MS/MS) as previously described
[27]—except that ADMA-d
7 was incorporated as the internal
standard, sample supernatant was dried to completion and
reconstituted in mobile phase, and a Phenomenex Luna Silica
column was used.
DDAH2 Genotyping
Buccal swabs were obtained from all patients for genetic
analysis. DNA was extracted using the Qiagen EZ1 DNA tissue kit
(QIAGEN Inc., Valencia, CA). A 572 base-pair region of the
DDAH2 gene on chromosome 6p21.3 (Figure 2) was then
amplified by PCR using Platinum PCR Supermix High Fidelity
(Life Technologies Corporation, Carlsbad, CA) for 35 cycles.
Sequencing was limited to this region of the DDAH2 gene because
it encompasses an area identified as a second promoter region and
includes two polymorphisms that have been previously described
to have functional significance—the 2871 6g/7g insertion/
deletion polymorphism (which lies adjacent to a transcription
factor binding site) [28] and the 2449 G/C SNP (rs805305)
[11,21,29,30]. Denaturation was performed at 96uC for 2 min-
utes, followed by 5 cycles of 20 seconds at 96uC, 50 seconds at
60uC, and 30 seconds at 72uC, then 30 cycles of 22 seconds at
94uC, 50 seconds at 55uC, and 30 seconds at 72uC, and a final
extension at 72uC for 10 minutes. Sequencing was performed
using a Big Dye Terminator v1.1 cycle sequencing kit (Life
Technologies Corporation, Carlsbad, CA) with M13 forward and
M13 reverse primers as sequencing primers (Figure S1), and DNA
analysis was performed with 3130xl Genetic Analyzer Data
Collection software v3.0 (Life Technologies Corporation, Carls-
bad, CA).
Statistical Methods
Statistical analysis was performed using Statistical Package for
the Social Sciences (SPSS Version 12.1, Chicago, IL) and SAS 9.2
(SAS institute Inc., Cary, NC). Since ADMA concentrations, IS,
and vasoactive infusion-free days were not normally distributed,
results are expressed as the median with interquartile range (IQR)
and were compared using the Mann-Whitney U and Kruskal-
Wallis tests. Deviation from Hardy-Weinberg equilibrium and
differences in genotype distributions and type of shock between
groups were evaluated using the chi-square and Fisher’s exact tests
(two-sided). For the 2449GC SNP, dominant and recessive
models were analyzed for differences in plasma ADMA and shock
type. Since population-based studies have reported racial differ-
ences in allele frequency for the 2449G/C SNP, with the CC
genotype observed more commonly in African than European
cohorts (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.
cgi?rs=805305), logistic regression analysis was used to adjust for
sex and race as potential confounders. P-values#0.05 were
considered significant.
Results
Of the 1789 patients consecutively admitted to the PICU during
the study period, 85 (4.8%) met criteria for severe sepsis or septic
shock. Thirty-seven of these patients were excluded, with 30 (63%)
of the 48 eligible septic patients initially enrolled. Thirty age-
matched febrile and 30 age-matched healthy control patients were
also initially enrolled. Of these 90 patients, 82 (91%) consented to
DDAH2 genotyping and were included in this analysis (Figure 3).
Patient characteristics are shown in Table 2. There was a higher
proportion of males in the healthy control group (p=0.03) and a
trend towards a higher proportion of Black and Hispanic patients
in the septic and febrile groups (p=0.08). Bacteremia and
pneumonia were the most common sources of infection in septic
patients.
Observed numbers of each genotype conformed to the Hardy-
Weinberg equilibrium. To determine whether the DDAH2
polymorphisms were associated with susceptibility to severe
sepsis/septic shock, we compared genotype distributions between
septic and control patients. While there were trends toward an
increased frequency of the minor allele 2871 7g and 2449CC
homozygotes in septic patients, overall genotype frequencies did
not differ significantly between the three groups (Table 3) or
between septic and combined non-septic controls for the 2871
6g/7g insertion/deletion polymorphism (p=0.10) or the 2449G/
C SNP (p=0.25).
Consistent with the results from all 90 patients [17], the median
plasma ADMA on day 1 in the subset in this study was lower in
septic patients (0.39, IQR 0.30–0.56 mmol/L) compared with
febrile (0.44, IQR 0.40–0.52 mmol/L) and healthy (0.57, IQR
0.53–0.65) controls (p,0.001). There was no difference in plasma
Table 1. Hemodynamic Shock Types.
Warm Shock Cold Shock
Pulse pressure Wide ($30 mm Hg) Narrow (,30 mm Hg)
Diastolic blood pressure Decreased Normal or Increased
Distal pulses Bounding Absent or Weak
Capillary refill ‘‘Flash’’ or #2 seconds ‘‘Delayed’’ or .2 seconds
Extremity temperature Warm Cool
doi:10.1371/journal.pone.0033355.t001
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6g or 6g/7g genotypes (Table 4). For the 2449G/C SNP,
however, decreasing concentrations of ADMA were observed
between genotypes for the septic patients, with the highest levels in
CC homozygotes (0.55, IQR 0.49–0.64 mmol/L), intermediate
levels in GC heterozygotes (0.37, IQR 0.30–0.56 mmol/L), and
lowest levels in GG homozygotes (0.34, IQR 0.25–0.39 mmol/L)
on day 1 (p=0.01) but not day 3 (p=0.33; Figure 4). In the septic
patients with at least one G allele at the 2449 position (G-
dominant model), plasma ADMA was significantly lower com-
pared to those with the 2449CC genotype on day 1 but not day 3
(Table 4). When a G-recessive model was assumed, median
ADMA was also lower on day 1 in those with the 2449GG
homozygous genotype (0.34, IQR 0.25–0.39 mmol/L) compared
with the 2449GC/CC genotypes (0.50, IQR 0.34–0.61 mmol/L,
p=0.009) but not on day 3 (data not shown, p=0.20). For the
febrile and healthy controls combined, there were no differences in
ADMA between distinct 2871 6g/7g (p=0.24) or 2449G/C
(p=0.11) genotypes.
Overall, 18 (62%) of the septic patients presented with ‘‘warm’’
shock and nine (31%) with ‘‘cold’’ shock. The remaining two
patients met criteria for severe sepsis but not shock. For the
2449G/C SNP, there was a significant difference in genotype
frequencies between septic patients with ‘‘warm’’, ‘‘cold’’, and no
shock when a G-dominant model was assumed (p=0.01), but not
with a G-recessive model (p=0.48). Nine of the 20 patients (45%)
with at least one G allele at the 2449 position presented with
‘‘cold’’ shock compared to none with the 2449CC homozygous
genotype (Table 4). However, significant racial differences were
observed in the distribution of 2449G/C polymorphisms, with
64% of all Black patients having the CC genotype compared with
14% of all White and Hispanic patients (p,0.001). When race was
controlled using logistic regression, the association of shock type
with the 2449G/C SNP in the septic patients became non-
significant (p=0.32). There was no association between type of
shock and different 2871 6g/7g genotypes, nor were differences
noted for IS on days 1 or 3 or in the number of vasoactive
infusion-free days for septic patients with different 2871 6g/7g or
2449G/C genotypes (Table 4).
Although there was no difference in plasma ADMA level
between septic patients with warm or cold shock overall (p=0.42),
ADMA remained lower in the septic patients with at least one
2449G allele compared with 2449CC homozygotes regardless of
type of shock (Figure 5).
Figure 2. DDAH2 gene. Schematic representation of DDAH2 gene (adopted from www.ncbi.nlm.nih.gov/gene/23564), including the upstream
promoter, the ATG translation start site, and the 2871 6g/7g and 2449 G/C polymorphisms. Exons are numbered 1–7. Exon 1 is non-coding, but this
area and intron 1 appear to contain a second promoter region.
doi:10.1371/journal.pone.0033355.g002
Figure 3. Patient screening and study enrollment. Flow diagram of patient screening and enrollment.
doi:10.1371/journal.pone.0033355.g003
DDAH2 Polymorphisms in Pediatric Septic Shock
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33355Discussion
This study found that a specific genetic polymorphism—the
presence of at least one G allele at the 2449 position—within
the DDAH2 gene was associated with low plasma ADMA
concentrations in children with severe sepsis or septic shock but
not in non-septic controls. This same polymorphism was also
associated with an increased likelihood of presenting with
vasoconstricted or ‘‘cold’’ shock, with nearly half exhibiting this
clinical phenotype compared with exclusively ‘‘warm’’ or no
shock seen in the patients with the 2449CC homozygous
genotype. To our knowledge, this pilot study is the first to
associate genetic variability in the DDAH2 gene with different
hemodynamic profiles observed clinically in pediatric sepsis. Our
results suggest that genotypic differences in the regulation of NO
metabolism may contribute to phenotypic variability in sepsis
pathophysiology.
Marked hemodynamic variability occurs in pediatric septic
shock. In one study using pulmonary artery catheter measure-
ments in children with fluid-refractory septic shock, only 20%
exhibited the classic high cardiac output-low SVR (‘‘warm’’) shock
state, while 58% had low cardiac output-high SVR (‘‘cold’’) shock.
Similar findings were reported in a more recent study, with the
majority of children with community-acquired sepsis exhibiting
‘‘cold’’ shock [31]. Reflecting these clinical observations, current
guidelines recommend a stratified therapeutic approach in
pediatric sepsis with vasopressors utilized for persistent ‘‘warm’’
shock and inotropes with or without vasodilators for ‘‘cold’’ shock
[26]. The factors underlying individual differences in shock states
in sepsis, however, remain unknown.
Alterations in NO bioavailability affect both myocardial and
vascular function and therefore directly impact the adequacy of
microvascular blood flow, tissue perfusion, and organ function [5].
ADMA decreases NO production through competitive inhibition
of all NOS isoforms and intracellular arginine transport [10], and
differences in circulating ADMA concentrations have been
associated with risk for development of essential hypertension,
atherosclerosis, and pulmonary vascular disease [32]. In adults
with sepsis, several studies have found elevated plasma ADMA
levels [12,33], particularly in those with septic shock requiring
Table 2. Patient Characteristics.
Septic Febrile Healthy P value
n=29 n=27 n=26
Age (years) 7.4 (2.3–15.4) 10.4 (2.6–16.1) 10.0 (4.3–15.1) 0.83
Sex, % male 48 33 69 0.03
Race/Ethnicity, n (%)
White, non-Hispanic 9 (31) 7 (26) 17 (65) 0.08
White, Hispanic 13 (45) 13 (48) 5 (19)
Black 6 (21) 6 (22) 2 (8)
Other 1 (3) 1 (4) 2 (8)
PIM-2 6.6 (1.5–9.8) 1.0 (0.8–1.2) 0.8 (0.8–0.9) ,0.001
PELOD 20 (11–21) 0 (0-0) 0 (0-0) ,0.001
Hospital LOS (days) 11 (7–17) 2 (1–4) 1 (1-1) ,0.001
Source of Infection, n (%) 0.007
Bacteremia 12 (42)
a 0N / A
Pneumonia 7 (24) 1 (4)
Viral syndrome 3 (10) 6 (22)
Meningitis 0 1 (4)
Urinary tract infection 0 1 (4)
No identified source 7 (24) 18 (66)
Type of Shock, n (%)
Vasodilated (‘‘warm’’) 18 (62)
Vasoconstricted (‘‘cold’’) 9 (31)
No shock 2 (7)
N/A=not applicable.
aGram-positive organism=4, gram-negative organism=7, mixed gram-positive and gram-negative organisms=1.
doi:10.1371/journal.pone.0033355.t002
Table 3. DDAH2 Genotype Frequencies.
DDAH2 Genotype Septic Febrile Healthy P value
a
n=29 n=27 n=26
2871 6g/7g Insertion/Deletion
6g/6g 24 (83) 26 (96) 24 (92) 0.96
6g/7g 5 (17) 1 (4) 2 (8)
2449G/C SNP
GG 10 (34) 8 (30) 7 (27) 0.75
GC 10 (34) 13 (48) 15 (58)
CC 9 (32) 6 (22) 4 (15)
aControlled for sex and race.
doi:10.1371/journal.pone.0033355.t003
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may also have important hemodynamic effects in critical illness.
However, in pediatric sepsis, where ‘‘cold’’ shock states are more
common, we previously found plasma ADMA to be decreased but
did not associate ADMA with shock type in that study [17].
The two DDAH enzymes are responsible for 80–90% of
ADMA metabolism and provide an important regulatory
mechanism for NO synthesis, and therefore, NO bioavailability
[35]. Prior studies have shown that changes in DDAH activity
cause alterations in intracellular ADMA in concentrations
Table 4. ADMA, type of shock, and vasoactive infusion requirements in septic patients
a.
2871 6g/6g 2871 6g/7g P value
n=24 n=5
ADMA, day 1 (mmol/L) 0.38 (0.30–0.56) 0.50 (0.34–0.59) 0.49
ADMA, day 3 (mmol/L) 0.47 (0.36–0.60) 0.45 (0.41–0.60) 0.71
Type of Shock, n (%)
Warm Shock 15 (63) 3 (60) 0.42
Cold Shock 8 (33) 1 (20)
None 1 (4) 1 (20)
Inotrope score (day 1)
b 11 (10–18) 10 (5–17) 0.76
Inotrope score (day 3)
b 6 (0–14) 6 (2–23) 0.56
Vasoactive infusion-free days 25 (21–26) 25 (23–27) 0.80
2449 G/G or G/C 2449 CC P value
n=20 n=9
ADMA, day 1 (mmol/L) 0.36 (0.30–0.41) 0.55 (0.49–0.64) 0.008
ADMA, day 3 (mmol/L) 0.45 (0.36–0.56) 0.58 (0.39–0.81) 0.20
Type of Shock, n (%)
Warm Shock 11 (55) 7 (78) 0.01
Cold Shock 9 (45) 0
None 0 2 (22)
Inotrope score (day 1)
b 10 (10–16) 13 (5–18) 0.98
Inotrope score (day 3)
b 6 (0–14) 0 (0–23) 0.67
Vasoactive infusion-free days 25 (22–26) 26 (22–27) 0.30
aData are presented as median (IQR), unless indicated.
bInotrope score=dopamine+dobutamine+(nor-/epinephrine6100)+(milrinone610)+(vasopressin610)
25.
doi:10.1371/journal.pone.0033355.t004
Figure 4. Relationship between plasma ADMA concentration and the DDAH2 2449G/C genotype in septic patients. Plasma ADMA
concentrations differed according to 2449G/C genotype on day 1 but not day 3. ADMA was highest in septic patients with 2449CC homozygous
genotype, intermediate in 2449GC heterozygotes, and lowest in the GG homozygotes on day 1 (p=0.01, panel A). While a similar trend in plasma
ADMA was observed on day 3, the difference was not significant (p=0.33, panel B).
doi:10.1371/journal.pone.0033355.g004
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found predominantly in endothelial and immune cells, where it co-
localizes with endothelial and inducible NOS, respectively.
Pharmacologic inhibition of DDAH increases ADMA, which
leads to endothelium-dependent vasoconstriction [20,37] and
alters the behavior of circulating lymphocytes [38], supporting
the importance of the ADMA-DDAH pathway in regulating NO-
mediated vascular and immune function. The identification of
genetic polymorphisms that influence expression or activity of the
DDAH2 enzyme is therefore intriguing as factors that could affect
immune response, susceptibility to infection, and hemodynamic
changes that may ultimately impact microvascular blood flow and
organ perfusion in pediatric sepsis.
We focused on two polymorphisms within the promoter region
of the DDAH2 gene with previously described functional
significance. The 2871 6g/7g insertion/deletion polymorphism
has been shown to alter the expression and activity of the DDAH2
enzyme in vitro [28] and the 2449G/C SNP has been associated
with alterations in plasma ADMA [11] and clinical outcomes
[21,29]. Despite the potential influence on immune function,
neither polymorphism was associated with an increased suscepti-
bility to severe sepsis or septic shock in our study, although we did
find a higher percentage of patients with the rare 2871 7g allele in
the septic group. Jones et al. observed that this 2871 7g allele led
to an increase in basal DDAH2 expression in cultured human
umbilical vein endothelial cells compared with the 2871 6g
variant [28]. In contrast, we did not observe a difference in plasma
ADMA, as a surrogate measure of DDAH2 activity, between
2871 6g/7g genotypes, although the rare occurrence of the 7g
allele may have limited our analysis. The 2449G/C SNP was
evaluated in a previous study of 47 adult patients with severe sepsis
or septic shock and carriage of the 2449G allele was associated
with an increased serum ADMA concentration [11]. These
findings contrast with our study, in which we found the 2449G
allele associated with lower ADMA levels. These conflicting results
may reflect that the DDAH2 isoform contributes little to
circulating ADMA, as it is more likely that DDAH1 regulates
systemic ADMA metabolism [39,40]. Alternatively, as DDAH2
activity is influenced by multiple factors other than genetics,
including availability of L-arginine [41], inflammatory cytokines
[10], and negative feedback by NO itself [42], the association of
DDAH2 genotype with plasma ADMA may be influenced by
different factors in distinct populations.
While we did not find a relationship between plasma ADMA
and type of shock, patients with at least one 2449G allele were
more likely to exhibit ‘‘cold’’ shock compared with CC
homozygotes. Given that the anticipated outcome of ADMA-
induced inhibition of NO synthesis should be to oppose vascular
relaxation, it is reasonable to expect that a polymorphism
associated with decreased plasma ADMA should predispose to
increased NO availability, vasodilatation, and ‘‘warm’’ shock.
Since patients with the 2449G allele exhibited lower plasma
ADMA levels irrespective of shock type (Figure 5), the association
between this polymorphism and low ADMA may be more of an
epiphenomenon and DDAH2 genotype may influence hemody-
namics through a mechanism other than circulating ADMA. The
disassociation between DDAH2 genotype, plasma ADMA, and
hemodynamic phenotype is supported by previous studies. Wang
et al. reported no difference in serum ADMA with DDAH2
silencing, but still observed reduced NO-regulated vascular
changes [39]. Maas et al. found an increased risk for hypertension
in patients with the 2449 GG genotype despite no association
with plasma ADMA [30]. The 2449G allele was also shown to be
less common than the CC homozygous genotype in adult patients
needing vasopressor support following cardiac surgery [21], and
although ADMA levels were not measured, the increased
prevalence of the 2449G allele in patients with a higher SVR
in that study is consistent with our finding that patients with at
least one 2449G allele were more likely to exhibit ‘‘cold’’, or high-
SVR, shock.
Limitations of our study include reliance on clinical assessment
to differentiate ‘‘warm’’ versus ‘‘cold’’ shock rather than direct
hemodynamic measurements of cardiac output and SVR and lack
of standardization of vasoactive therapy. Since patients may evolve
from a warm to a cold shock state (or vice versa), either through
natural progression of the septic response or as a consequence of
pharmacological intervention, we chose to focus on the association
of DDAH2 polymorphisms and shock state at initial presentation to
minimize the influence of vasoactive therapy. However, differenc-
es in timing of presentation after onset of infection may itself have
influenced hemodynamic state at PICU admission. The associa-
tion of DDAH2 polymorphisms with hemodynamic changes after
precise initiation of a septic insult and the natural evolution of the
septic response in the absence of pharmacologic intervention
would be best studied in animal models. Furthermore, we did not
differentiate between use of inotrope, vasopressor, and vasodilator
agents, which may have contributed to the lack of association
between DDAH2 genotype and vasoactive infusion requirements.
We also recognize that the most important limitation of our
study is the small sample size, which increases the risk for spurious
conclusions about the association of genetic polymorphisms with
clinical variables. To address this concern, three important
questions need to be answered [43]: Are the studied populations
homogeneous? Does the polymorphism of the gene under study
cause a relevant alteration in the level or function of the gene
product? Does the product of the studied gene play an important
role in the pathogenesis of the disease? The study cohort was
Figure 5. Plasma ADMA and shock type. All of the septic shock
patients with the 2449CC homozygous genotype exhibited ‘‘warm’’
shock. While day 1 plasma ADMA concentration did not differ between
‘‘warm’’ and ‘‘cold’’ shock (p=0.42), when compared with 2449CC
homozygous patients with shock, ADMA was significantly lower in
those with the 2449G allele for ‘‘cold’’ shock (p=0.02) and trended
lower for ‘‘warm’’ shock (p=0.09).
doi:10.1371/journal.pone.0033355.g005
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heterogeneous population of septic children with controls matched
only for age [17]. Given the association of Black race with both the
2449CC genotype and ‘‘warm’’ shock, we are not able to
differentiate whether the 2449G/C SNP itself influences type of
shock or is simply a marker for an alternative genetic or
environmental difference between racial groups. Further studies
in larger, more homogeneous populations are necessary. Second,
although the 2871 6g/7g polymorphism has been shown to
directly affect enzyme expression in vitro and the 2449G/C SNP
has been associated with variable ADMA concentrations in clinical
studies, it is not known to what extent genetic differences directly
alter expression or activity of the DDAH2 enzyme in vivo
compared with other regulatory mechanisms, such as oxidative
stress, arginine availability, and NO-induced inhibition. Finally,
while increasing evidence supports the importance of DDAH in
the regulation of NO bioactivity through ADMA metabolism in
cardiovascular disease [20,44], the direct effects of DDAH2-
induced changes in intracellular ADMA concentration on NO
bioactivity and outcomes in sepsis has not been adequately studied.
Therefore, we present this pilot study as a first step, exploratory
analysis of a biologically plausible mechanism linking genetic
differences to variability in hemodynamic shock in pediatric sepsis,
a clinically observed phenomenon which remains poorly under-
stood.
In conclusion, we studied whether two known functional
polymorphisms in the DDAH2 gene are associated with plasma
ADMA concentration, distinct hemodynamic states, and cardio-
vascular dysfunction in pediatric septic shock. We found that the
2449G SNP was associated with both decreased plasma ADMA
and an increased likelihood of presenting with ‘‘cold’’ shock in
pediatric sepsis. Although racial differences emerged as an
important confounder that mitigated the association of genotype
with shock type, these results support and justify the need to study
DDAH2 polymorphisms in larger, more homogeneous cohorts to
examine whether genotypic differences in NO metabolism
contribute to phenotypic variability in sepsis pathophysiology.
An improved understanding of individual differences in NO
metabolism could help to better target therapeutic interventions to
critically ill children with hemodynamic compromise.
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